- Ticker
- GTH
- Price
- 4.03
- Stock movement up
- +0.01 (0.12%)
- Company name
- Genetron Holdings Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Diagnostics & Research
- Market cap
- 127.29M
- Ent value
- 377.99M
- Price/Sales
- 0.24
- Price/Book
- 0.23
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 34.17%
- 3 year return
- -58.11%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-07-22
DIVIDENDS
GTH does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.24 |
| Price to Book | 0.23 |
| EV to Sales | 0.70 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 31.62M |
| EPS (TTM) | -20.45 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 540.38M |
| Gross profit (TTM) | 219.96M |
| Operating income (TTM) | -513.30M |
| Net income (TTM) | -633.49M |
| EPS (TTM) | -20.45 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 40.70% |
| Operating margin (TTM) | -94.99% |
| Profit margin (TTM) | -117.23% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 176.27M |
| Net receivables | 257.93M |
| Total current assets | 708.95M |
| Goodwill | 0.00 |
| Intangible assets | 32.07M |
| Property, plant and equipment | 0.00 |
| Total assets | 975.33M |
| Accounts payable | 63.05M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 389.87M |
| Total liabilities | 426.97M |
| Shareholder's equity | 548.36M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -115.53% |
| Return on Assets | -64.95% |
| Return on Invested Capital | -115.53% |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.02 |
| Daily high | 4.05 |
| Daily low | 4.02 |
| Daily Volume | 412K |
| All-time high | 91.92 |
| 1y analyst estimate | 1.34 |
| Beta | 0.50 |
| EPS (TTM) | -20.45 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| GTH | S&P500 | |
| Current price drop from All-time high | -95.62% | -0.02% |
| Highest price drop | -97.51% | -56.47% |
| Date of highest drop | 29 Sep 2022 | 9 Mar 2009 |
| Avg drop from high | -70.21% | -11.26% |
| Avg time to new high | 63 days | 12 days |
| Max time to new high | 786 days | 1805 days |
COMPANY DETAILS
Marketcap
127.29M
Marketcap category
Small-cap
Description
Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.
Employees
993
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner